Guangzhou Pharmaceuticals Group Co., Ltd.

Guangzhou Pharmaceutical Group Co., Ltd. is a wholly state-owned company authorized by the Guangzhou Municipal Government to operate and manage state-owned assets. It is mainly engaged in the research and development and manufacturing of Chinese patent medicines and botanical medicines, chemical raw materials and preparations, biological medicines, general health products, commercial logistics and distribution, and medical and health services. It is a large enterprise group integrating science, industry, and trade that Guangzhou City focuses on supporting the development of. GPHL owns one listed company, "Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd." (listed in Hong Kong H shares and Shanghai A shares) and nearly 30 member companies. After years of careful building and accelerated development, it has gradually formed four business sectors unique to GPHL, namely "Great Southern Medicine", "Big Health", "Big Commerce" and "Big Medical", as well as three new business formats: "E-commerce", "Capital Finance" and "Medical Devices". In 2017, GPHL became the second state-owned enterprise in Guangzhou to exceed 100 billion. The ranking of China's top 500 companies was promoted from 160th in 2019 to 155th in 2020. GPHL was listed among the Fortune Global 500 for the first time, ranking 468th. In the 2021 list of the world's most valuable pharmaceutical brands, GPHL entered the top 20 in the world for the first time, ranking 19th. It has been ranked first in the "Top 100 Chinese Pharmaceutical Industry List" for many consecutive years. GPHL has a history of 421 years. It is recognized that it is endowed with “red genes”, “longevity genes” and “innovation genes”, and has achieved brilliant achievements and a great future.